Who is sponsoring NCT06983158?

NCT06983158 is sponsored by Capsida Biotherapeutics, Inc..

What condition does NCT06983158 study?

NCT06983158 studies Developmental and Epileptic Encephalopathy.

What is the status of NCT06983158?

NCT06983158 is currently SUSPENDED.

Last reviewed 2025-10-01 · How we verify

A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy

NCT06983158 PHASE1, PHASE2 SUSPENDED

The goal of this clinical trial is to learn about the safety of CAP-002 gene therapy in children with Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy. It will also provide information about whether CAP-002 demonstrates efficacy in treating children with STXBP1 with and without seizures. Participants will have a single infusion of CAP-002, visit the clinic regularly for 2 years for checkups and tests and have seizures recorded in a diary by their caregiver.

Details

Lead sponsor	Capsida Biotherapeutics, Inc.
Phase	PHASE1, PHASE2
Status	SUSPENDED
Enrolment	12
Start date	Thu Jul 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 20 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Developmental and Epileptic Encephalopathy

Interventions

gene therapy

Countries

United States